Advisor Resource Council Makes New Investment in Royalty Pharma PLC (NASDAQ:RPRX)

Advisor Resource Council acquired a new position in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 90,577 shares of the biopharmaceutical company's stock, valued at approximately $2,595,000.

Several other large investors have also recently bought and sold shares of the business. Nissay Asset Management Corp Japan ADV raised its position in Royalty Pharma by 0.7% in the fourth quarter. Nissay Asset Management Corp Japan ADV now owns 48,481 shares of the biopharmaceutical company's stock worth $1,238,000 after acquiring an additional 349 shares in the last quarter. National Bank of Canada FI raised its position in Royalty Pharma by 21.8% in the fourth quarter. National Bank of Canada FI now owns 2,074 shares of the biopharmaceutical company's stock worth $53,000 after acquiring an additional 371 shares in the last quarter. Sherbrooke Park Advisers LLC increased its position in shares of Royalty Pharma by 1.1% in the fourth quarter. Sherbrooke Park Advisers LLC now owns 34,891 shares of the biopharmaceutical company's stock valued at $890,000 after buying an additional 380 shares in the last quarter. Sanctuary Advisors LLC increased its position in shares of Royalty Pharma by 0.9% in the fourth quarter. Sanctuary Advisors LLC now owns 41,854 shares of the biopharmaceutical company's stock valued at $1,068,000 after buying an additional 388 shares in the last quarter. Finally, MassMutual Private Wealth & Trust FSB increased its position in shares of Royalty Pharma by 76.4% in the first quarter. MassMutual Private Wealth & Trust FSB now owns 956 shares of the biopharmaceutical company's stock valued at $30,000 after buying an additional 414 shares in the last quarter. Hedge funds and other institutional investors own 54.35% of the company's stock.

Royalty Pharma Price Performance

Shares of RPRX traded up $0.54 during trading hours on Monday, reaching $35.40. 3,357,019 shares of the company traded hands, compared to its average volume of 3,647,296. The company has a quick ratio of 1.56, a current ratio of 1.56 and a debt-to-equity ratio of 0.68. The stock has a market capitalization of $19.90 billion, a PE ratio of 19.14, a price-to-earnings-growth ratio of 1.79 and a beta of 0.48. Royalty Pharma PLC has a fifty-two week low of $24.05 and a fifty-two week high of $35.71. The stock has a fifty day simple moving average of $33.20 and a 200 day simple moving average of $31.35.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating analysts' consensus estimates of $0.99 by $0.07. The business had revenue of $839.00 million for the quarter, compared to analyst estimates of $724.69 million. Royalty Pharma had a return on equity of 24.71% and a net margin of 48.23%. As a group, research analysts predict that Royalty Pharma PLC will post 4.49 EPS for the current fiscal year.

Royalty Pharma Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Friday, May 16th were paid a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.49%. The ex-dividend date of this dividend was Friday, May 16th. Royalty Pharma's payout ratio is currently 47.57%.

Analyst Ratings Changes

A number of research analysts have recently weighed in on RPRX shares. Wall Street Zen upgraded Royalty Pharma from a "hold" rating to a "buy" rating in a research report on Saturday. Citigroup restated a "buy" rating on shares of Royalty Pharma in a research report on Friday, March 28th. Finally, Morgan Stanley started coverage on Royalty Pharma in a research report on Friday, May 16th. They issued an "overweight" rating and a $51.00 price target for the company. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Royalty Pharma presently has a consensus rating of "Buy" and a consensus price target of $47.33.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.